[Different botulinum toxins and their specifications]
- PMID: 19576490
- DOI: 10.1016/S0151-9638(09)74532-6
[Different botulinum toxins and their specifications]
Abstract
Botulinum neurotoxin A was the first developed for therapeutic and then esthetic uses, Botox first and then Dysport. These two products differ on a few points, explaining their nonequivalence of units: American and British tests of the mouse LD50 units based on solutions that were not identical and 500microg vs 150microg serum albumin dose in the excipient. The neurotoxin- accessory protein complexes were also different: 900 kDa homogeneous for Botox, 500 kDa heterogeneous for Dysport, giving greater diffusion for Dysport, but this is under debate and could result from an excessive conversion ratio. Clinical comparative studies, often with weak methodology, have defined an ideal ratio between these two products, guaranteeing efficacy, but without an overly pronounced diffusion. In the first publications for neurological and ophthalmological indications, the conversion ratio between Dysport and Botox was high, 4:1, and sometimes higher. However, today, particularly for cosmetic indications, the trend is toward a much lower ratio, 2.5:1, or perhaps less for dyshidrosis. This lower ratio has an economic incidence: Dysport is less expensive and therefore more competitive. The price of Dysport's cosmetic product, Azzalure, compared to the price of Vistabel, which is Botox's cosmetic presentation, has not yet been defined in France. The other A toxins, Xeomin, and the Asian toxins, MyoBloc (botulinum toxin type B), tested compared to Botox, have a slightly lower efficacy.
Similar articles
-
Pharmacology of botulinum toxin: differences between type A preparations.Eur J Neurol. 2006 Feb;13 Suppl 1:2-10. doi: 10.1111/j.1468-1331.2006.01438.x. Eur J Neurol. 2006. PMID: 16417591 Review.
-
Botulinum toxin type B (Myobloc).Dermatol Surg. 2003 May;29(5):496-500; discussion 500. doi: 10.1046/j.1524-4725.2003.29120.x. Dermatol Surg. 2003. PMID: 12752517 Review.
-
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000. Drugs R D. 2010. PMID: 20698714 Free PMC article.
-
Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.J Drugs Dermatol. 2011 Sep;10(9):1013-5. J Drugs Dermatol. 2011. PMID: 22052270 Review.
-
Botulinum toxin: examining duration of effect in facial aesthetic applications.Am J Clin Dermatol. 2010;11(3):183-99. doi: 10.2165/11530110-000000000-00000. Am J Clin Dermatol. 2010. PMID: 20369902 Review.
Cited by
-
OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.Toxins (Basel). 2020 Jun 13;12(6):393. doi: 10.3390/toxins12060393. Toxins (Basel). 2020. PMID: 32545832 Free PMC article.
-
A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.Toxins (Basel). 2022 Oct 28;14(11):739. doi: 10.3390/toxins14110739. Toxins (Basel). 2022. PMID: 36355989 Free PMC article.
-
Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.Toxins (Basel). 2021 Nov 22;13(11):824. doi: 10.3390/toxins13110824. Toxins (Basel). 2021. PMID: 34822610 Free PMC article.
-
Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids.Dermatol Ther (Heidelb). 2013 Dec;3(2):179-89. doi: 10.1007/s13555-013-0033-y. Epub 2013 Aug 16. Dermatol Ther (Heidelb). 2013. PMID: 24318416 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources